Back to Journals » Cancer Management and Research » Volume 12

RETRACTED ARTICLE: Cell Differentiation Agent-2 (CDA-2) Inhibits the Growth and Migration of Saos-2 Cells via miR-124/MAPK1

Authors Li Q, Li G, Liu C, Chen N, Deng B, Xie Y

Received 8 February 2020

Accepted for publication 15 May 2020

Published 15 June 2020 Volume 2020:12 Pages 4541—4548


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Ahmet Emre Eşkazan

This paper has been retracted.

Li Q, Li G, Liu C, Chen N, Deng B, Xie Y. Cancer Manag Res. 2020;12:4541–4548.

The Editor and Publisher of Cancer Management and Research wish to retract the published article. Concerns were raised regarding the integrity of the published study. The authors were contacted and asked to provide original data that would verify the validity of the reported findings. The authors responded to our queries and provided some data, however much of the expected original data was unavailable and the authors were unable to adequately verify the reported findings. The Editor determined the reported study to be invalid and requested for the article to be retracted. The authors agreed with this decision.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Creative Commons License © 2020 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.